Lifeline Biotechnologies, Inc.

Provides Patient Data for System Improvements

RENO, NV— (BUSINESS WIRE) — October 25, 2007—Lifeline Biotechnologies, Inc. (OTCPK: LLBT - News) announced today that patient data is being provided to Nanyang Technical University which the engineers will utilize for further development and improvement the Company’s First Warning System, a system designed to assist in the early detection of breast cancer.  

Jim Holmes, Lifeline’s CEO stated “We are providing our engineering consultants with approximately 300 cases of patient data.  This data has been selected from over 600 cases obtained from patient testing which we conducted at Ohio State University Hospital, Green Memorial Hospital and the most recently in Argentina. We expect, based on the preliminary analysis by these engineers, an improvement in the First Warning System’s interpretive software, which could assist in the early detection of cancer.”  

Dr. Keith, Lifeline’s Medical Director added “We are well on the way to initiating substantive discussions with our Singapore collaborators regarding a new series of patient testing using an Asian population.  Recent epidemiologic data suggest that incidence of breast cancer is increasing rapidly in Asia as well as worldwide.  We believe the Asian population is an ideal group for further study.” 

About Lifeline Biotechnologies, Inc: 

The Company is focused on completing the development of the First Warning System™, designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System™ is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year providing a potential savings of up to $2.8 billion annually. The First Warning System™ could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually, assuming the following are successfully completed:  the development of the First Warning System™, the completion of clinical trials and FDA pre-marketing clearance.  Upon the completion of the aforementioned steps, Lifeline will commence marketing its early breast cancer detection system. Management’s current and best estimate is that the required steps could take two to four years to conclude.  The future value of the Company could be dependent upon these successes.  Lifeline competes in the capital markets for financing.  The financial markets are very competitive and dilution has occurred as a result of previous funding and may occur again in order to secure future capital.  More information is available at the Company's Web site: www.lbtn.com.  

Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934.  Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.  

Contact

For more information, please visit

www.lbtn.com  

or Investor Relations